Christian Meyer Joins uniQure as Chief Medical Off
Post# of 301275
AMSTERDAM, Netherlands, Oct. 4, 2013 (GLOBE NEWSWIRE) -- uniQure B.V., a leader in human gene therapy, today announced that Christian Meyer, M.D., Ph.D., has joined the company as Chief Medical Officer. Dr. Meyer has 18 years of clinical research experience with both biotechnology companies and large pharma, with particular expertise in the development of treatments for rare diseases, including Acute Intermittent Porphyria and lysosomal storage disorders.
"Since joining uniQure early in the year as a consultant, Christian has built an extremely experienced clinical development team. This team is operating already at a high level as our pipeline programs advance into further clinical evaluation in the next 12-24 months," said Jörn Aldag, CEO of uniQure. "Christian's leadership in clinical development as well as his focus on rare diseases is a tremendous resource for the company and we are very glad to welcome him officially to the management team."
"I have been impressed with both the company's achievements in gaining approval for Glybera in the European Union and the potential of our gene therapy approach," added Dr. Meyer. "I am fully committed to reaching the next level of development for our pipeline."
Christian Meyer joins uniQure from Cardoz AB where he spent three years as Chief Medical Officer. From 2006 to 2010, Dr. Meyer held leadership positions in clinical development at Symphogen A/S, where he was Senior Vice President for Medical Affairs and Vice President, Clinical Development. Prior to Symphogen, he played an important role in clinical development at Zymenex A/S and spent five years in clinical development at Novo Nordisk A/S. Dr. Meyer received both his M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.
About uniQure
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. www.uniqure.com .
Press release (PDF): http://hugin.info/157414/R/1733550/580459.pdf
Jorn Aldag CEO uniQure T: +31 20 566 8014 Media inquiries: MacDougall Biomedical Communications Doug MacDougall (US) +1 781 235_3060 Gretchen Schweitzer (Europe) +49 172 861 8540
(0)
(0)